Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 16, 2026, 5:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Topotecan - study Clear all
Completed Phase 2 Interventional Results available

Cabazitaxel Compared to Topotecan for the Treatment of Small Cell Lung Cancer

NCT01500720
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Cabazitaxel, Topotecan
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
179 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
5
States / cities
Muscle Shoals, Alabama • Omaha, Nebraska • Lebanon, New Hampshire + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Safety Study of ABT-888 Plus Topotecan Hydrochloride to Treat Patients With Solid Tumors and Lymphomas

NCT00553189
View directory record Official record
Conditions
Solid Tumors, Lymphomas
Interventions
ABT-888, Topotecan
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 1, 2017 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 3 Interventional

Combination Chemotherapy in Treating Patients With Previously Untreated Rhabdomyosarcoma

NCT00003958
View directory record Official record
Conditions
Adult Malignant Mesenchymoma, Adult Rhabdomyosarcoma, Alveolar Childhood Rhabdomyosarcoma, Childhood Malignant Mesenchymoma, Embryonal Childhood Rhabdomyosarcoma, Embryonal-botryoid Childhood Rhabdomyosarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Previously Untreated Childhood Rhabdomyosarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma
Interventions
dactinomycin, vincristine sulfate, cyclophosphamide, therapeutic conventional surgery, radiation therapy, topotecan hydrochloride, filgrastim, sargramostim, laboratory biomarker analysis
Biological · Drug · Procedure + 2 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 49 Years
Enrollment
702 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2002
U.S. locations
1
States / cities
Arcadia, California
Source: ClinicalTrials.gov public record
Updated Jun 16, 2013 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 1Phase 2 Interventional

Amifostine Plus Topotecan in Treating Patients With Myelodysplastic Syndrome

NCT00003415
View directory record Official record
Conditions
Leukemia, Myelodysplastic Syndromes
Interventions
amifostine trihydrate, topotecan hydrochloride
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2002
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 30, 2013 · Synced Sep 16, 2026, 5:05 PM EDT
Withdrawn Phase 1Phase 2 Interventional

Phase I/II Trial of Rhenium 188-P2045 in Small Cell Lung Cancer and Other Advanced Neuroendocrine Carcinomas

NCT02030184
View directory record Official record
Conditions
Small Cell Lung Cancer (SCLC), Neuroendocrine (NE) Tumors, Large Cell Neuroendocrine (NE) Tumors
Interventions
Rhenium Re 188-P2045
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 16, 2019 · Synced Sep 16, 2026, 5:05 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

ME-344 Given in Combination With Hycamtin® in Patients With Solid Tumors

NCT02100007
View directory record Official record
Conditions
Solid Tumors
Interventions
ME-344, Topotecan
Drug
Lead sponsor
MEI Pharma, Inc.
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Scottsdale, Arizona • Aurora, Colorado • Chicago, Illinois + 5 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Safety and Effectiveness of Topotecan HCl to Treat HIV-Infected Patients With AIDS-Related Progressive Multifocal Leukoencephalopathy (PML)

NCT00002395
View directory record Official record
Conditions
HIV Infections, Leukoencephalopathy, Progressive Multifocal
Interventions
Topotecan
Drug
Lead sponsor
SmithKline Beecham
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Los Angeles, California • San Francisco, California • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Vincristine Sulfate, Topotecan Hydrochloride, and Cyclophosphamide With or Without Bevacizumab in Treating Young Patients With Refractory or First Recurrent Extracranial Ewing Sarcoma

NCT00516295
View directory record Official record
Conditions
Ewing Sarcoma of Bone, Extraosseous Ewing Sarcoma, Peripheral Primitive Neuroectodermal Tumor, Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor
Interventions
topotecan hydrochloride, vincristine sulfate, cyclophosphamide, bevacizumab
Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
1 Year to 29 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 1, 2014 · Synced Sep 16, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional

Study of Sacituzumab Govitecan Versus Standard of Care in Participants With Previously Treated Extensive Stage Small Cell Lung Cancer

NCT06801834
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Cancer (ES-SCLC)
Interventions
Sacituzumab Govitecan (SG), Topotecan, Amrubicin (Japan only), Lurbinectedin (regions/countries where approved and available)
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years and older
Enrollment
695 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
23
States / cities
Anchorage, Alaska • Hot Springs, Arkansas • Anaheim, California + 19 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Sep 16, 2026, 5:05 PM EDT
Recruiting Phase 1 Interventional

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

NCT04701645
View directory record Official record
Conditions
Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Cancer Stage III, Ovarian Cancer Stage IV, Fallopian Tube Cancer Stage IV, Fallopian Tube Cancer Stage III
Interventions
Microdevice
Combination Product
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 17, 2026 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

N2012-01: Phase 1 Study of Difluoromethylornithine (DFMO) and Celecoxib With Cyclophosphamide/Topotecan

NCT02030964
View directory record Official record
Conditions
Neuroblastoma
Interventions
DFMO, Celecoxib, Cyclophosphamide, Topotecan
Drug
Lead sponsor
New Approaches to Neuroblastoma Therapy Consortium
Other
Eligibility
2 Years to 30 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
11
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2025 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Weekly Topotecan in Combination With Carboplatin in Two Different Schedules for Refractory and/or Advanced Solid Tumors

NCT00193583
View directory record Official record
Conditions
Cancer
Interventions
Topotecan, Carboplatin
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2011 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Open-label Study of Topotecan and Pazopanib in Advanced Solid Tumors

NCT00732420
View directory record Official record
Conditions
Solid Tumours
Interventions
topotecan, pazopanib
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 12, 2017 · Synced Sep 16, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional

Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma

NCT06647953
View directory record Official record
Conditions
Pleuropulmonary Blastoma
Interventions
Biospecimen Collection, Bone Scan, Computed Tomography, Cyclophosphamide, Dactinomycin, Dexrazoxane, Doxorubicin, Echocardiography Test, Ifosfamide, Magnetic Resonance Imaging, Multigated Acquisition Scan, Patient Observation, Positron Emission Tomography, Topotecan, Ultrasound Imaging, Vincristine
Procedure · Drug · Biological + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 21 Years
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
80
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 71 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Dinutuximab and Irinotecan Versus Irinotecan to Treat Subjects With Relapsed or Refractory Small Cell Lung Cancer

NCT03098030
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Dinutuximab, Irinotecan, Topotecan
Biological · Drug
Lead sponsor
United Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
483 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
40
States / cities
Anchorage, Alaska • Goodyear, Arizona • Tucson, Arizona + 35 more
Source: ClinicalTrials.gov public record
Updated Dec 8, 2020 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Comparison of Four Combination Chemotherapy Regimens Using Cisplatin in Treating Patients With Stage IVB, Recurrent, or Persistent Cancer of the Cervix

NCT00064077
View directory record Official record
Conditions
Cervical Adenocarcinoma, Cervical Adenosquamous Carcinoma, Cervical Squamous Cell Carcinoma, Recurrent Cervical Carcinoma, Stage IVB Cervical Cancer
Interventions
Cisplatin, Gemcitabine Hydrochloride, Paclitaxel, Quality-of-Life Assessment, Topotecan Hydrochloride, Vinorelbine Tartrate
Drug · Other
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
513 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2018
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 16, 2018 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 3 Interventional Results available

Combination Chemotherapy and Surgery With or Without Isotretinoin in Treating Young Patients With Neuroblastoma

NCT00499616
View directory record Official record
Conditions
Neuroblastoma
Interventions
carboplatin, cyclophosphamide, doxorubicin hydrochloride, etoposide, topotecan hydrochloride, Isotretinoin, Surgery, Filgrastim
Drug · Procedure
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 12 Years
Enrollment
464 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2021
U.S. locations
166
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 137 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2021 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

TMC (Topotecan, Cyclophosphamide and Melphalan) for Multiple Myeloma

NCT01039025
View directory record Official record
Conditions
Myeloma
Interventions
Topotecan, Cyclophosphamide, Melphalan, Peripheral Blood Stem Cells
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 70 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 6, 2018 · Synced Sep 16, 2026, 5:05 PM EDT
Active, not recruiting Early Phase 1 Interventional

A Study of N9 Chemotherapy in Children With Neuroblastoma

NCT04947501
View directory record Official record
Conditions
Neuroblastoma, Pediatric Cancer
Interventions
Cyclophosphamide, Topotecan, Vincristine, Doxorubicin, Ifosfamide, Etoposide, Carboplatin, Mesna
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
1 Year to 19 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Topotecan Plus Etoposide in Treating Patients With Recurrent Ovarian, Peritoneal, or Fallopian Tube Cancer

NCT00003967
View directory record Official record
Conditions
Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
Interventions
etoposide, topotecan hydrochloride
Drug
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
6
States / cities
Iowa City, Iowa • Baltimore, Maryland • Camden, New Jersey + 2 more
Source: ClinicalTrials.gov public record
Updated May 26, 2013 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy in Treating Patients With Advanced Cancer

NCT00003331
View directory record Official record
Conditions
Chronic Myeloproliferative Disorders, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
Interventions
fluorouracil, leucovorin calcium, topotecan hydrochloride
Drug
Lead sponsor
NYU Langone Health
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 27, 2011 · Synced Sep 16, 2026, 5:05 PM EDT
Recruiting Phase 3 Interventional

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07365241
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
ABBV-706, Topotecan, Lurbinectedin, Amrubicin
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
531 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
32
States / cities
Birmingham, Alabama • Mobile, Alabama • Goodyear, Arizona + 27 more
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 2 Interventional

Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

NCT00319969
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Amrubicin, Topotecan
Drug
Lead sponsor
Celgene Corporation
Industry
Eligibility
18 Years and older
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
47
States / cities
Birmingham, Alabama • Phoenix, Arizona • Berkeley, California + 40 more
Source: ClinicalTrials.gov public record
Updated Sep 29, 2009 · Synced Sep 16, 2026, 5:05 PM EDT
Completed Phase 2 Interventional Results available

Linsitinib or Topotecan Hydrochloride in Treating Patients With Relapsed Small Cell Lung Cancer

NCT01533181
View directory record Official record
Conditions
Recurrent Small Cell Lung Carcinoma
Interventions
Laboratory Biomarker Analysis, Linsitinib, Pharmacological Study, Topotecan Hydrochloride
Other · Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
10
States / cities
Scottsdale, Arizona • Tampa, Florida • Atlanta, Georgia + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 13, 2016 · Synced Sep 16, 2026, 5:05 PM EDT